Click here to close now.




















Welcome!

News Feed Item

Epic Sciences and Collaborators to Present Six Novel Abstracts at ASCO GU Addressing the Clinical Applicability of Epic's Circulating Tumor Cell Technology in Prostate Cancer

Studies address technical sensitivity, specificity, pharmacodynamics, heterogeneity and patient selection relevant to prostate cancer patient management

SAN DIEGO and SAN FRANCISCO, Jan. 29, 2014 /PRNewswire/ -- Epic Sciences, in collaboration with the company's academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel abstracts at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference, taking place January 30 to February 1 in San Francisco. The studies were employed to evaluate Epic's circulating tumor cell (CTC) technology platform across several parameters in metastatic castration resistant prostate cancer (mCRPC).  These parameters include sensitivity, specificity, pharmacodynamics and heterogeneity for use in patient selection and monitoring of clinical trials.

CTCs are cells that escape from solid tumors and enter the bloodstream. Epic's CTC technology can identify, count and characterize CTCs from a blood sample.  Epic's technology represents a novel and non-invasive way to understand disease progression, metastatic risk, therapeutic selection, and therapeutic effectiveness.

"The ability to accurately quantitate and biologically characterize circulating tumor cells for drug targets and the underpinnings of tumor progression from a simple blood sample can improve our ability to assess an individual patients' cancer in real-time, enabling more personalized cancer treatments," said Howard Scher, M.D., Chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center. "Accurate diagnostic tools are needed to inform treatment selection, understand whether treatments are working, and allow us to better manage a patient's cancer."

"The questions addressed in these studies with our collaborators represent critical technical and clinical questions associated with the robustness of future oncology diagnostic solutions utilizing real-time liquid biopsies," said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. "Epic's technology has an industry-leading level of sensitivity in detecting circulating tumor cells and the added benefit of enhanced molecular characterization of CTCs to develop crucial tools for better cancer management."

The six abstracts will be presented in ASCO GU General Poster Sessions A & B on January 30 and 31:

  • Abstract #78:  Sequential monitoring and characterization of circulating tumor cells (CTCs) using the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
  • Abstract #132:  Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).
  • Abstract #177: Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
  • Abstract #198:  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in classic and apoptotic circulating tumor cells (CTC) in metastatic castration-resistant prostate cancer (mCRPC).
  • Abstract #209: CK- and small nuclear size circulating tumor cell (CTCs) phenotypes in metastatic castration-resistant prostate cancer (mCRPC).
  • Abstract #266:  Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer.

Epic is currently involved in 27 individual pharma-sponsored oncology clinical studies occurring around the world and is collaborating with top research centers to create new diagnostic and companion diagnostic products.

About Epic Sciences

Epic Sciences, Inc. is a privately held company that is developing new diagnostics to improve and personalize the treatment and management of cancer. Epic's mission is to provide a better way to detect cancer and to monitor and personalize cancer treatments.  Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic has partnered with leading pharmaceutical companies, major cancer centers, and the National Cancer Institute (NCI) to advance its technology to improve clinical oncology and cancer therapeutic development.

For more information, please visit http://www.epicsciences.com or follow on Twitter @epicsciences.  To learn more about Epic's partnering program and clinical trial services, please email [email protected]

SOURCE Epic Sciences

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
Red Hat is investing in Tesora, the number one contributor to OpenStack Trove Database as a Service (DBaaS) also ranked among the top 20 companies contributing to OpenStack overall. Tesora, the company bringing OpenStack Trove Database as a Service (DBaaS) to the enterprise, has announced that Red Hat and others have invested in the company as a part of Tesora's latest funding round. The funding agreement expands on the ongoing collaboration between Tesora and Red Hat, which dates back to Febr...
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
SYS-CON Events announced today that DataClear Inc. will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The DataClear ‘BlackBox’ is the only solution that moves your PC, browsing and data out of the United States and away from prying (and spying) eyes. Its solution automatically builds you a clean, on-demand, virus free, new virtual cloud based PC outside of the United States, and wipes it clean...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership ab...
A producer of the first smartphones and tablets, presenter Lee M. Williams will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ETwater. In his session at @ThingsExpo, Lee Williams, COO of ETwater, will talk about how he is now applying his experience in mobile technology to the design and development of the next generation of Environmental and Sustainability Services at ET...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Cloud and datacenter migration innovator AppZero has joined the Microsoft Enterprise Cloud Alliance Program. AppZero is a fast, flexible way to move Windows Server applications from any source machine – physical or virtual – to any destination server, in any cloud or datacenter, using its patented container technology. AppZero’s container is also called a Virtual Application Appliance (VAA). To facilitate Microsoft Azure onboarding, AppZero has two purpose-built offerings: AppZero SP for Azure,...
WSM International, the pioneer and leader in server migration services, has announced an agreement with WHOA.com, a leader in providing secure public, private and hybrid cloud computing services. Under terms of the agreement, WSM will provide migration services to WHOA.com customers to relocate some or all of their applications, digital assets, and other computing workloads to WHOA.com enterprise-class, secure cloud infrastructure. The migration services include detailed evaluation and planning...
This Enterprise Strategy Group lab validation report of the NEC Express5800/R320 server with Intel® Xeon® processor presents the benefits of 99.999% uptime NEC fault-tolerant servers that lower overall virtualized server total cost of ownership. This report also includes survey data on the significant costs associated with system outages impacting enterprise and web applications. Click Here to Download Report Now!
IBM’s Blue Box Cloud, powered by OpenStack, is now available in any of IBM’s globally integrated cloud data centers running SoftLayer infrastructure. Less than 90 days after its acquisition of Blue Box, IBM has integrated its Blue Box Cloud Dedicated private-cloud-as-a-service into its broader portfolio of OpenStack® based solutions. The announcement, made today at the OpenStack Silicon Valley event, further highlights IBM’s continued support to deliver OpenStack solutions across all cloud depl...